T-VEC in Non-melanoma Skin Cancer

  • End date
    Feb 26, 2022
  • participants needed
  • sponsor
    University of Zurich
Updated on 26 March 2021
melanoma skin
skin cancer
squamous cell carcinoma
non-melanoma skin cancer
carcinoma of skin
merkel cell carcinoma
advanced squamous cell carcinoma


Evaluation of the mechanism of Action of talimogene laherparepvec (T-VEC) in patients with locally advanced non-melanoma skin cancer.


This study evaluates the administration of T-VEC in non-melanoma skin cancer. The aim is to evaluate the effectiveness, safety and tolerability of T-VEC in patients with non-melanoma skin cancer through determination of local immune effects after repeated T-VEC injections.

Condition Basal cell carcinoma, Neuroendocrine carcinoma, Carcinoma, Squamous cell carcinoma, Merkel cell carcinoma, Vulvar Dysplasia and Carcinoma, Advanced Malignancies, Cutaneous Lymphoma, Non-melanoma Skin Cancer, Non-melanoma Skin Cancer, basal cell carcinomas, basal cell carcinoma of skin, epidermoid carcinoma, squamous cell cancer, Non-melanoma Skin Cancer, Non-melanoma Skin Cancer
Treatment Talimogene Laherparepvec (T-VEC)
Clinical Study IdentifierNCT03458117
SponsorUniversity of Zurich
Last Modified on26 March 2021


Yes No Not Sure

Inclusion Criteria

Subjects Age 18 years
histologically confirmed diagnosis of locally advanced squamous cell carcinoma, basal cell, carcinoma, Merkel cell carcinoma or cutaneous T cell lymphoma
at least 1 injectable cutaneous lesion 20 mm in longest Diameter or multiple injectable lesions that in Aggregate have a longest Diameter of 50 mm
Eastern Cooperative Oncology Group-Status (ECOG Status) 0 or 1
Adequate organ functions

Exclusion Criteria

Hypersensitivity to T-VEC or any of ist components
Presence of organ and lymph node metastases
history or evidence of active autoimmune disease that requires systemic Treatment
Evidence of clinically significant immunosuppression
active herpetic skin lesions or prior complications hereof
pregnancy, breast feeding
requires intermittent or chronic systemic Treatment with an antiherpetic drug
acute or chronic active Hepatitis B or C infection or HIV infection
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note